Literature DB >> 14674991

Human DNA damage checkpoints and their relevance to soft tissue sarcoma.

Hiroyuki Hattori1, Masahiko Kuroda, Tsuyoshi Ishida, Koutarou Shinmura, Shuzou Nagai, Kiyoshi Mukai, Atsuhiro Imakiire.   

Abstract

Soft tissue sarcoma (STS) is a malignant neoplasm, arising in mesenchymal tissues, that is difficult to treat clinically because it can be highly resistant to chemo-radiotherapy. At present, the mechanism of that resistance remains unclear. Cell cycle checkpoints engender strict control of cell proliferation, arresting the cell cycle to provide time for repair or apoptosis when DNA damage is induced by unprogrammed extrinsic events. These pathways involve at least two checkpoints: one at the G1/S transition and one at the G2/M transition. The p53 gene, which is mutated in several malignant tumors, plays an important role in DNA repair at the G1/S transition; however, there is little information on the G2/M checkpoint in STS. In the present study, several proteins (phospho-p53, -cdc25, -cdc2, -Chk1 and -Chk2) involved in checkpoint pathways were investigated using immunohistochemistry in STS specimens. Most STSs maintain a well-preserved G2/M checkpoint despite the loss of the G1/S checkpoint (phospho-p53: 4.9% (2/41); -cdc25: 41% (17/41); -cdc2: 61% (25/41); -Chk1: 29% (12/41); -Chk2: 46% (19/41)). Furthermore, in a postoperative chemotherapy case the number of cells positive for phospho-cdc25 and -Chk2 was higher in a recurrent tumor than in the primary tumor (n = 7, P = 0.046 < 0.05, Wilcoxon signed-ranks test). These findings indicate that the G2/M checkpoint pathway is well preserved and might contribute to the chemotherapeutic resistance associated with STS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14674991     DOI: 10.1111/j.1440-1827.2004.01585.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  2 in total

1.  CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Authors:  G Zoppoli; S Solier; W C Reinhold; H Liu; J W Connelly; A Monks; R H Shoemaker; O D Abaan; S R Davis; P S Meltzer; J H Doroshow; Y Pommier
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

2.  Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.

Authors:  Zhihui Wang; Mette S Førsund; Claes G Trope; Jahn M Nesland; Ruth Holm; Ana Slipicevic
Journal:  Cancer Med       Date:  2018-07-02       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.